parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.05 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in urothelial cells	0.75
chemistry Open Targets	hard to drug	0.40
trials ClinicalTrials.gov	130 Parkinson's trials, 2 stopped	0.97
literature PubMed	37 Parkinson's papers of 11,715	0.52
pathways Reactome	2 pathways; mostly protein handling	0.90

No case: the score is under the bar. Receipt 5200

receipt 5209: GAN in dopamine neurons, braak

power: full sample +0.03 (p 0.915, n 18), 95% CI -0.45 to +0.49. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.04 (p 0.867, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.09 (p 0.728, n 18). could be the mix.
skeptic: leave-one-out range -0.09 to +0.15, sign flips 7; without severely affected donors +0.03 (p 0.915, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GAN in dopamine neurons.

case closed: nothing better to follow up.

receipt 5208: GAN in astrocytes, braak

power: full sample +0.19 (p 0.455, n 18), 95% CI -0.31 to +0.60. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.18 (p 0.471, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.18 (p 0.465, n 18). could be the mix.
skeptic: leave-one-out range +0.07 to +0.30, sign flips 0; without severely affected donors +0.19 (p 0.455, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GAN in astrocytes.

case closed: nothing better to follow up.

loading the receipts